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ABSTRACT  
Objective. To examine whether the change in maternal insulin, insulin resistance, and cytokines 
that occurs in the last trimester is related to infant adiposity at birth in non-diabetic, 
overweight/obese pregnant women.  
Subjects. Non-diabetic women with a pregravid body mass index (BMI) of >25, ages 18-40 
years, were enrolled in the study at 26 weeks gestation. Women with diabetes, hypertension, or 
tobacco use were excluded.  
Methods.  At 26 and 37 weeks gestation, maternal serum cytokines (TNF-α, IL-6, adiponectin), 
glucose and insulin were measured. A 2-hour oral glucose tolerance test (OGTT) using a meal 
was conducted at 37 weeks in the General Clinical Research Center. Insulin resistance (HOMA-
IR, %B) was calculated from fasting glucose and insulin. Infant weight and length were reported 
by the mother or obtained from the medical record. Indices of adiposity were calculated and 
included percentiles for weight-for-length (WHO Anthro software), and Ponderal Index (wtkgx 
703 / heightm
2). 
Analysis. Predictor variables were change in maternal insulin, HOMA-IR, %B, TNF-α IL-6, and 
adiponectin from 26-37 weeks; outcome variables were percentiles for infant weight-for-length 
percentile and Ponderal Index. T-test was used to determine differences in these same maternal 
variables between categories of infant adiposity, grouped by Ponderal Index percentile and 
weight for length percentile.  
Results. Forty-five mother infant dyads, (28% non-Hispanic Black, 21% non-Hispanic White, 
51% Latino/Hispanic) were included. Infants at or above the 90th percentile for Ponderal Index 
comprised 23% of the sample. Maternal variables were not correlated with Ponderal Index or 
  iii 
weight for length at birth (P>0.05) No significant differences in maternal variables were 
observed between categories of infant Ponderal Index or weight for length at birth (P>0.05).  
Conclusions. In conclusion, changes in maternal insulin resistance and cytokines associated with 
obesity were not related to infant adiposity at birth in non-diabetic women. Not all 
overweight/obese pregnant women are unequivocally at risk for higher infant adiposity. 
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Introduction 
During pregnancy, significant maternal metabolic alterations are necessary to support 
fetal growth and development. One such alteration is mild, progressive insulin resistance, which 
allows glucose to be shunted to the developing fetus.1,2 Gestational diabetes mellitus (GDM) is 
known to cause macrosomia,3 yet, maternal glucose tolerance exists along a spectrum, with many 
women falling between “normal” and a diagnosis of GDM. Changing, and even dissenting 
guidelines as to the diagnosis of GDM and impaired glucose tolerance (IGT) has complicated the 
evaluation of risk among overweight and obese pregnant women.  
In addition to glucose tolerance, other factors synergistically impact fetal growth and size 
at birth. Maternal pre-pregnancy body mass index (BMI) and gestational weight gain have been 
associated with fetal overgrowth, and increased maternal adiposity precipitates abnormal 
circulating levels of biologically active cytokines. The cumulative levels of cytokines produced 
by adipose tissue and the placenta may have an impact on fetal placental nutrient transfer. In the 
obese pregnant woman, higher placental and serum levels of TNF-α and IL-6, alongside 
decreased adiponectin, can impact placental macronutrient uptake and maternal insulin 
resistance, further connecting the metabolic factors at play in the obese pregnant woman.4-6  
Few studies have attempted to tease apart the impact of hyperglycemia without a 
diagnosis of GDM, maternal obesity, and maternal cytokines on infant adiposity at birth,7 while 
others have failed to show a connection between individual maternal cytokines and infant size.8 
The findings of this analysis will outline which, if any, maternal metabolic attributes are 
significantly different among stratifications of infant adiposity, and will assign specificity to the 
general premise that obese pregnancies result in infant overgrowth. 
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Literature Review 
Obesity in Pregnancy 
Despite the public health attention aimed at obesity reduction in the United States, 
maternal overweight persists as a significant health issue. Rates of obesity and overweight 
steadily rose from 17.6% and 23.0% to 20.5% and 24.3%, respectively, from 2003 to 2009.9 
These trends transcended age and ethnicity, with 1 in 5 women entering into pregnancy with 
excess adiposity, independent of age and race classification.9 Should these trends continue, it is 
statistically likely that less than half of future pregnancies will arise from mothers having a 
normal body weight.  
Obesity augments a pattern of insulin resistance and inflammation required for normal 
pregnancy initiation and progression.10-12 In the obese state, accumulated adipose tissue begets 
higher levels of circulating cytokines and free fatty acids, which ultimately worsen existing 
insulin resistance, up-regulate maternal-fetal nutrient transfer, and increase the need for insulin 
secretion from an already taxed pancreas.13 Obese pregnancies are considered high risk due to 
the associated pregnancy complications, including GDM, pre-eclampsia, fetal overgrowth, 
Caesarian section, postpartum hemorrhage, infection, and intrauterine death, with risks 
increasing in a linear fashion as BMI increases.14 
Definition of Fetal Overgrowth  
The definition of and terminology surrounding fetal overgrowth varies. Macrosomia, one 
descriptive term, describes fetal overgrowth in reference to an absolute weight in grams. The 
most common cut point for macrosomia is a birthweight above 4000 grams, though other sources 
have defined macrosomia as birth weights above 4100 grams, 4500 grams, or 5000 grams.15 The 
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prevalence of macrosomia has been increasing over time; with national prevalence data reporting 
that 6.3% of infants were born weighing over 4000 grams in the year 2010.16 
One of the criticisms associated with using this traditional definition of macrosomia as a 
description of fetal overgrowth stems from its lack of relation to gestational age and infant 
length.17 To address the connection to gestation age, standardized growth charts reflecting 
percentiles can be used to categorize infants as large for gestational age (LGA) or small for 
gestational age (SGA). These categorizations correspond to birth weights >90th percentile and 
<10th percentile, respectively, with appropriate for gestational age (AGA) infants falling between 
these cutoff points.17 The Centers for Disease Control (CDC) reports that in 2005, 9% of infants 
were born large for gestational age, which is an increase from the rate of 6.6% reported from 
1985-1998.18,19  
To assess fetal overgrowth in connection with infant length, BMI, weight-for-length 
percentile, and Ponderal Index are additional indices that provide estimates of adiposity. BMI is 
calculated using the formula {wtkgx 703 / heightm
2}; Ponderal Index is calculated using the 
formula {100 x wtg / heightcm
3}.20 The cubed measurement of the Ponderal Index allows for more 
appropriate scaling of height, which yields a more accurate estimation of adiposity for short-
statured individuals. Though both indices have been reported in assessment infant 
anthropometry, Ponderal Index is generally considered to be more appropriate for use in infants, 
as the CDC does not recommend calculation of BMI for infants under the age of two.21 Weight 
for length, calculated using World Health Organization (WHO) percentile data, is another index 
to determine relative adiposity. The CDC recommends using WHO charts are suggested for use 
in infants up to the age of two years, starting at birth; these charts were formulated using 
breastfed infants in optimal conditions.22 
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Complications of Fetal Overgrowth 
Fetal overgrowth is associated with both short and long-term complications. Large infants 
are at increased risk for imminent complications at delivery including shoulder dystocia, brachial 
plexus injury, aspiration and asphyxia, skeletal injuries, hypoglycemia, and fetal death.15 These 
risk factors frequently necessitate delivery by Caesarean section, which is a major surgical 
procedure that is not devoid of risk. Beyond increased rates of Caesarean section, maternal 
complications related to fetal macrosomia include increased risk of hemorrhage, prolonged labor, 
and infection.15 Long after the perinatal period, infants born LGA continue to be at risk for 
several chronic diseases as children and adults. Obesity, metabolic syndrome, and type 2 diabetes 
have all been associated with increased size at birth.23-25  
Etiology of Fetal Overgrowth 
The determinants of fetal size at birth are numerous; some are modifiable, while others 
are not. Non-modifiable contributors to infant size include maternal and paternal heights, infant 
gender, race, and maternal characteristics such as age, parity, and birth history.26 Mothers who 
have previously given birth to a LGA infant are more likely to do so again, even if they don’t 
develop GDM.27 Additionally, as maternal age and parity increases, there is an increased 
association with heavier birthweights.28 Genetic factors are another important consideration, with 
genetic variation explaining 30-80% of the variance in birth weight.29 
One of the most significant and highly modifiable risk factors for fetal overgrowth is 
excessive gestational weight gain. A gain of more than 11 kilograms during pregnancy is 
strongly associated with birth of a LGA infant,30 and total gestational weight gain is a strong 
predictor of macrosomia.31 Mothers who have smaller weight gains in pregnancy consistently 
tend to deliver smaller babies than those with higher gestational weight gain.27 Also, maternal 
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weight status prior to pregnancy is strongly associated with infant birthweight; elevated pre-
pregnancy BMI has been shown to be an independent risk factor for high birthweight.32 
It is known that the risk of macrosomia increases in parallel to the length of gestation, but 
there is some disagreement as to the relevance of this association past the due date. It has been 
proposed that fetal growth follows a curvilinear trend where rates of growth decline as gestation 
progresses. Mechanistically, this may be due to progressive aging of the placenta, which results 
in uteroplacental insufficiency.33 It has also been suggested that growth becomes limited past a 
fetal weight of 3000-3200 grams (6.6-7.1 pounds), with further growth being determined 
predominantly by the intrauterine environment.34 In contrast to these hypotheses, there have been 
studies that report a fully linear relationship where risk of macrosomia directly increases as 
gestation extends past the due date.35 
Maternal Hyperglycemia and Fetal Overgrowth 
In addition to maternal weight status and length of gestation, maternal hyperglycemia has 
been shown in observational studies to be associated with higher infant birth weight. There is a 
well-established relationship between GDM and fetal overgrowth, where infants born to diabetic 
mothers are consistently more likely to be LGA, with up to 35% of such infants above the 95th 
percentile for weight.3 Additionally, infants born LGA to diabetic mothers tended to have a 
higher Ponderal index than infants born LGA to mothers with normal glucose tolerance.20 
However, vital statistics have shown that more macrosomic infants are born to non-GDM 
mothers than those with GDM.36 Observational studies conducted in non-GDM women have 
shown associations between increased maternal glucose levels at 24-32 weeks of pregnancy and 
many of the adverse outcomes associated with fetal overgrowth.36 Maternal serum insulin among 
non-GDM mothers has also been associated with higher Ponderal Index at birth.37 
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Insulin and Glucose 
In normal metabolism, insulin stimulates glucose uptake from the blood into peripheral 
tissues where the nutrient is used to fuel cellular activities. In the fed state, a rise in blood 
glucose levels stimulates the pancreatic β cells to produce insulin and release it into the portal 
circulation. Insulin binds to insulin receptors (IR) on the cell surfaces of muscle and adipose 
cells, causing a conformational change in the β subunit of the insulin receptor. The change in the 
shape of the β subunit results in auto-phosphorylation of tyrosine stored therein, transforming the 
β subunit into a docking site for insulin receptor substrate-1 proteins (IRS). IRS-1 proceeds to 
recruit phosphatidyisonol 3-kinase (PTD3-kinase) to the cell membrane, a compound which is 
instrumental in the formation of phosphatidyisonol 3,4,5 tri-phosphate from phosphatidyisonol 
4,5 diphosphate. PTD 3,4,5 tri-phosphate is a potent activator of protein kinase B, a multi-
functional byproduct of insulin metabolism. Protein kinase B promotes translocation of GLUT-4 
receptors from internal cellular vesicles to the cell membrane, resulting in increased facilitated 
diffusion of glucose into the cell.38 Additionally, protein kinase B, along with its associated 
product phosphoprotein di-esterase, is instrumental in the promotion of glycolysis, whereby 
glucose is oxidized to harvest cellular energy in the form of ATP.  
Glucose Metabolism in Pregnancy 
Pregnancy is a naturally insulin-resistant condition initiated by a rise in the maternal 
hormones prolactin, progesterone, and estrogens.39 In late pregnancy, hepatic glucose production 
increases while peripheral tissue and hepatic sensitivity to insulin decline, the combined effects 
of which can result in insulin resistance of up to 50% in late pregnancy. Maternal insulin 
resistance is evidenced by a progressive rise in both fasting and postprandial glucose, along with 
an increased first and second phase insulin response.40,41 The function of maternal insulin 
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resistance is to shunt glucose, the primary fetal fuel, away from maternal cells and across the 
placenta, providing constant fuel to the fetus though maternal intake is intermittent throughout 
the day.1 Since maternal insulin does not cross the placenta, fetal insulin is produced in 
proportion to the supply of glucose received from the mother.42 In normal pregnancies, the 
maternal β cells in the islets of the pancreas adapt to this peripheral insulin resistance, secreting 
an appropriate amount of insulin to maintain blood glucose within a normal physiological range 
while adjusting to a metabolic milieu that promotes the use of non-carbohydrate substrates for 
maternal energy.40 
Glucose Metabolism in GDM 
In the diabetic state, metabolic adaptations fail to compensate for the progressive insulin 
resistance of pregnancy, leading to hyperglycemia.40 Considerable debate surrounds the 
pathogenesis of GDM in regards to the exact contributions of peripheral insulin resistance, 
hepatic glucose production, and β cell dysfunction leading to insulin deficit. A methodologically 
robust study by Catalano et al. found that women with GDM have lower insulin-stimulated 
glucose disposal in early pregnancy than women without GDM.13 As pregnancy progresses, this 
gap between GDM and non-GDM narrows, but peripheral insulin resistance continues to 
increase in both groups. Throughout gestation, GDM mothers show a gradual decrease in insulin 
release as evidenced by a decreased first-phase insulin response, signaling initial manifestation 
of β cell dysfunction. Additionally, in non-GDM women, insulin appropriately suppresses 
hepatic glucose production, up to 95%, whereas hepatic glucose production is suppressed by 
only 80% in GDM women. According to the model postulated by Catalano et al., the progressive 
decrease in insulin release, coupled with advancing insulin resistance throughout gestation and 
suboptimal suppression of hepatic glucose production, results in late-gestation hyperglycemia in 
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GDM women.13 Kuhl et al. has disagreed with this model, stating that the development of GDM 
cannot be contributed to a diminished release of insulin, but is more significantly related to post-
binding defects of insulin and peripheral insulin resistance.43 There is, however, a body of 
research which shows that β cell dysfunction is a common, perhaps universal, feature of GDM 
that has been observed across ethnicities.2,44 
In human subjects with GDM and type 2 diabetes, post-receptor defects in the insulin-
signaling pathway have been identified. Downregulation of the insulin-receptor substrate-1, 
which is an integral signaling molecule in the production of protein kinase B, results in decreased 
translocation of GLUT-4 transporters to the cell surface and subsequent impaired glucose 
absorption by myocytes and adipocytes.45 Additional disruption of tyrosine phosphorylation 
within the insulin receptor can disrupt the signaling pathway involved in insulin action.46 
Maternal insulin ineffectiveness will result in abnormally high levels of glucose in 
maternal blood, which will be freely transported across the placenta to the developing fetus. 
According to the Pedersen hypothesis, this maternal-induced infant hyperglycemia will promote 
insulin production by the fetus. Fetal insulin secretion promotes anabolism, which can result in 
increased fat deposition, macrosomia, and increased adiposity at birth.47  
Diagnostic Measures of GDM and IR 
The gold standard for evaluating insulin resistance during pregnancy is the 
hyperinsulinemic-euglycemic clamp technique developed by DeFronzo et al. in 1979.48 
Intravenous insulin is administered at a continuous rate, fixing plasma insulin to a threshold 
whereby hepatic glucose production is suppressed. Glucose is then infused at a variable rate, 
keeping the plasma glucose concentration constant. In the steady-state, the rate of glucose 
infusion is equal to the rate of whole body glucose disposal or metabolizable glucose (M), 
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providing an indication of tissue insulin sensitivity. When insulin is administered at a rate of 
40uU/m2 x min, a calculated M of <4.7 is considered reflective of insulin resistance.49 Because 
of its cost and cumbersome administration, this test is not routinely used to evaluate insulin 
resistance in pregnant women, but provides a standard by which other indices can be validated.  
Fasting plasma glucose and fasting plasma insulin are easily obtained, inexpensive 
indicators of maternal insulin resistance that can be used as both stand-alone measures and 
mathematical variables in derivative formulas. Elevated fasting glucose is well correlated with β 
cell dysfunction in pregnant women and has been associated with adverse fetal outcomes.50 
Women exhibiting normal levels of fasting glucose, 80mg/dL or less, are considered low-risk for 
developing GDM with a 95.4% specificity.36 Both fasting glucose and fasting insulin are 
elevated in GDM women compared to those with normal glucose tolerance in all trimesters of 
pregnancy.51 
The oral-glucose tolerance test (OGTT) is the gold standard used clinically to screen for 
and/or diagnose GDM in all pregnant women in the United States. During a 2-hour, 75g OGTT, 
a glucose load of 75 grams is given via a meal or drink, and glucose and insulin are measured at 
three time points: in the fasting state, 60 minutes after administration, and 120 minutes after 
administration. Three-hour, 100g OGTTs are also common. When plotted, areas under the curves 
for glucose and insulin can be calculated and used as indices of whole body insulin sensitivity, 
and other indices can be derived from OGTT data.52 
Clinical Diagnosis of GDM  
Unlike the clear diagnostic cut-points of overt diabetes in the general population, there 
continues to be a lack of consensus on what testing values or combination thereof constitute a 
diagnosis of GDM. Traditional guidelines published by the American Diabetic Association 
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(ADA) included an OGTT screening being conducted in at-risk pregnant women between 24 and 
28 weeks of pregnancy, with two or more abnormal values during the test considered to be 
diagnostic of GDM.53 In 2008, after the publication of the Hyperglycemia and Adverse 
Pregnancy Outcomes study, deliberations were held among the International Association of 
Diabetes and Pregnancy Study Groups, which suggested revision of the diagnostic guidelines for 
GDM. These new recommendations, which were accepted by the ADA (a) expanded screening 
to include all women, not just those with specific risk factors, (b) made one abnormal value 
during the OGTT, not two, diagnostic of GDM, and (c) published new cut-off values to be used 
during the OGTT, which for fasting, 1 hour, and 2 hours are 92mg/dL, 180mg/dL, and 
152mg/dL, respectively.54  
In contrast to the position of the ADA, the American College of Obstetrics and 
Gynecology (ACOG) has not adopted these new guidelines and continues to use their historical 
guidelines for the diagnosis of GDM. Using the ACOG guidelines, GDM is diagnosed via a two-
step process that does not include OGTT testing for women considered to be at low risk. Initial 
screening is done based on clinical history and risk factors, via a 50-gram, 1-hour glucose load 
test at 24-28 weeks gestation. For those deemed to be at risk, which includes obese pregnant 
women, a 100-gram, 3-hour OGTT is conducted. Diagnosis of GDM is made when two values 
during the OGTT exceed critical limits, which are defined by either (a) the plasma or serum 
glucose levels established by Carpenter and Coustan or (b) the plasma glucose levels designated 
by the National Diabetes Data Group (NDDG). The Carpenter and Coustan cut-off values are as 
follows for the fasting, 1 hour, 2 hour, and 3 hour timepoints: 95 mg/dL, 180mg/dL, 155 mg/dL, 
and 140mgdL, respectively. The NDDG cut-off values differ slightly with fasting limits set at 
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105mg/dL and one, two and three-hour limits set at 190mg/dL, 165mg/dL, and 145mg/dL, 
respectively.55 
The ACOG’s failure to lower the threshold for GDM diagnosis is based on the rationale 
that the results of post-HAPO randomized, controlled trials have not demonstrated definitive 
clinical advantage to conducting interventions at lower levels of hyperglycemia, along with 
concerns about rising healthcare costs associated with non-discriminative screening and 
widening diagnostic thresholds.55 This divergence in opinion between the ADA and the ACOG 
represents the lack of clarity in the clinical community regarding the exact contribution made by 
maternal hyperglycemia, which further calls into question the potential impact, cost-
effectiveness, and clinical usefulness of interventions in hyperglycemic women without GDM.  
GDM Versus Impaired Glucose Tolerance 
Due to the lack of consensus surrounding GDM diagnosis, many women with values 
above normal ranges, but below diagnostic criteria, fail to receive a diagnosis and subsequent 
intervention. Though the changes in ADA recommendations will serve to increase the diagnosis 
of GDM in general, there still exists a continuum of glucose intolerance that increases the risk 
for macrosomia and related complications in many women. In a cross-sectional examination by 
DiCianni et al., women exhibiting one abnormal value (OAV) during the ACOG-recommended 
OGTT were compared to a sample of GDM and normoglycemic counterparts.56 In this sample of 
over 4,000 women, the prevalence of OAV (18.7%) was equivalent to the prevalence of GDM 
(17.9%), with both groups being strikingly similar in their pre-pregnancy weights and amount of 
weight gain. Additionally, these groups had a similar prevalence of triglyceride elevation, a 
common characteristic of GDM stemming from impaired insulin action. As glucose tolerance 
worsened across the groups, decreases in β cell action and Insulin Sensitivity Index were seen in 
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nearly equal frequency between the OAV and GDM groups. Ultimately, the authors concluded 
that women with OAV were clinically indistinguishable from women with GDM and may be in 
need of intervention, should further clinical testing prove its efficacy.56  
Maternal Cytokines 
Mature adipocytes continuously secrete a variety of low molecular weight, protein-based 
messenger molecules, known collectively as cytokines, into circulating blood.57 During 
pregnancy, the placenta is another major production site for these hormone-like molecular 
messengers, and infant cord blood has been shown to contain variable amounts of cytokines.58  
Increasing evidence has associated maternal and fetal cytokines with short and longer-term infant 
growth, and though exact mechanisms are yet to be elucidated, placental nutrient transfer is 
likely a key tenant.58  
Adiponectin 
Adiponectin is a multi-meric peptide hormone involved in energy metabolism and 
regulation of systemic inflammation.59,60 Though most cytokines are secreted at relatively higher 
concentrations in the setting of excess adipose tissue, serum adiponectin is negatively correlated 
with obesity, and also depressed in disease states such as type 2 diabetes and coronary artery 
disease.4 The paradoxical lower concentration of adiponectin in obesity is a finding that has been 
consistent across ethnic groups.61 Most circulating adiponectin is made in adipose tissue, but the 
placenta also contributes a significant amount.62  
 Adiponectin acts as a key regulator of glucose and lipid metabolism via its action on 5'-
AMP-activated protein kinase (AMPK), a “master metabolic switch” responsible for the 
phosphorylation of key protein targets in pathways of glucose uptake and fatty acid oxidation.63 
In general, activation of AMPK results in suppression of triglyceride synthesis, lipolysis, and 
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insulin release, with concurrent increases in fatty acid oxidation and glucose uptake. In skeletal 
muscle, adiponectin’s activation of AMPK also reduces gluconeogenesis through actions on 
enzymes PEPCK and G6Pase. Overall, adiponectin, largely as a result of AMPK activation, 
leads to increased peripheral insulin sensitivity and improvements in glucose uptake in muscle 
and liver.59 To combat inflammation, adiponectin induces the release of the anti-inflammatory 
cytokines IL-10 and IL-1RA.  
In non-pregnant adults, low serum levels of adiponectin have been associated with 
hyperinsulinemia and insulin resistance.61 In pregnancy, maternal adiponectin levels have been 
shown to be consistently lower in mothers with GDM, with risk of GDM increasing by 20% for 
each 1 ng/mL decrease in serum adiponectin concentration.64,65 Despite evidence of 
hypoadiponectinemia in GDM pathogenesis, serum adiponectin levels are not sufficiently 
sensitive to detect the degree of glucose intolerance during pregnancy.4 Though the placenta 
releases adiponectin throughout pregnancy, this does not appear to have a direct effect on 
maternal serum levels.66 In pregnancies complicated by GDM, decreased placental adiponectin 
gene expression has been seen.67 
As an insulin-sensitizing agent, adiponectin is inherently tied to infant growth, which 
hinges upon adequately controlled, functional, maternal insulin resistance. Mechanistically, 
adiponectin affects infant growth via two routes: first, by acting in a systemic manner to impact 
the maternal metabolic milieu, and second, by moderating the insulin-stimulated placental 
nutrient transfer of macronutrients.68 Maternal adiponectin is not transferred across the placental 
barrier, therefore cord blood adiponectin is that which has been produced by infant adipocytes.58 
In several studies, adiponectin levels in cord blood are elevated alongside maternal levels, and 
often positively associated with infant birthweight.69-71 The higher average levels in newborn 
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cord blood are hypothesized to result from unique fat distribution in the newborn, as well as the 
relative immaturity of the newborn’s adipocytes.68 LGA newborns are, however, frequently 
found to have reduced adiponectin levels, which may be a result of the negative-feedback 
presented by more mature, hypertrophic adipocytes in this state of fetal overgrowth.68  
TNF-a 
 Tumor necrosis factor alpha (TNF-α) is a polypeptide signaling molecule produced by 
macrophages as well as other cells, which is responsible for systemic inflammation, insulin 
resistance, and apoptosis, among other functions.72 Serum TNF-α is considered a biomarker of 
inflammation, and elevated levels can indicate future risk for diabetes and cardiovascular 
disease.73 In hypertrophied adipocytes, macrophage recruitment via chemokines leads to over-
release of TNF-α, where it acts as a potent activator of c-Jun N-terminal kinases (JNK), which 
depress insulin sensitivity by inhibiting the signaling action of insulin receptor substrates, 
specifically IRS-1.38,73,74 Without proper activation of IRS-1, the transporter GLUT-4 cannot 
ultimately reach the cell surface, resulting in decreased glucose transfer from bloodstream to 
needy cell.75 Besides the direct disruption of insulin cell signaling, TNF-α indirectly impacts 
glucose uptake into muscle by down-regulating the transcription of adiponectin, an insulin-
sensitizing hormone.73 Insulin-resistant subjects, when matched for BMI, have been found to 
have three times more TNF-α release from adipose tissue than controls.76 
TNF-α has been found in maternal and placental tissues throughout gestation.51,62 
Moderate levels of TNF-α and related cytokines are necessary in pregnancy, fulfilling functions 
such as prostaglandin and hCG production and the initiation of labor.77 In the setting of pre-
gravid obesity, excess placental accumulation and release of TNF-α extends beyond normal 
pregnancy physiology and begets inflammation-based insulin resistance as described previously.5 
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TNF-α is positively, linearly associated with maternal BMI, while being inversely correlated 
with insulin sensitivity in late pregnancy.64,78  
Elevated placental and maternal serum levels of TNF-α may contribute to excessive fetal 
fat deposition. The placentas of obese neonates have been shown to have thrice the amount of 
TNF-α when compared to normal weight infants, and TNF-α is positively associated with infant 
weight at birth.79,80 One potential mechanism for the association of TNF-α and birth size is 
related to the ability of this cytokine to impact placental-fetal nutrient transport. At physiological 
concentrations, TNF-α increases placental amino acid transport system A activity by 100%, 
ultimately resulting in an increase in the amino acid uptake by the developing fetus.81 Therefore, 
TNF-α, a potent metabolic signaling molecule, may impact fetal growth via injurious effects on 
maternal insulin resistance and a direct physiological contribution to fetal over-nutrition.    
IL-6 
IL-6 is a multifunctional, pleiotropic cytokine involved in the acute phase inflammatory 
response, fertility, embryonic development, and tissue regeneration, among other functions.82,83 
IL-6 participates in one of two cell-signaling transduction pathways, which will either suppress 
or heighten inflammation.  In the first potential pathway, IL-6 binds to plasma membrane 
complexes housing glycoprotein 130, a ubiquitous cellular receptor. The transduction of this 
signal activates the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) 
cascade within the cell, resulting in the stimulation or repression of target gene transcription. 
This transduction is ultimately repressed by a negative feedback system of suppressors of 
cytokine signaling (SOCS), resulting in an overall decrease in inflammation.84,85 Alternately, IL-
6 can activate the NAPK (nitrogen-activated protein kinase) reaction cascade, which is not 
suppressed in the manner of the JAK signal transduction, and therefore promotes cellular 
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inflammation.86 Which pathway is activated may greatly depend on the state of the cell at any 
given time, as well as cell type, and the presence or absence of external stimuli.86 
A significant portion of circulating IL-6 is produced by adipose tissue87,88 and therefore 
serum IL-6 levels are positively correlated to weight status.6 The mechanism by which IL-6 
contributes to insulin resistance remains unclear, but adipocytes and hepatocytes appear to be 
most significantly affected. In-vitro exposure of adipocytes to high levels of IL-6 increases the 
expression of SOCS-3, an IRS-1 inhibitor, in fatty tissue,89 resulting in disruption of insulin 
signaling.90 In hepatocytes, highly consistent findings indicate an identical process of SOC-3 
production, IRS-1 disruption, and decreased insulin action. Conversely, in muscle, there is 
limited evidence that IL-6 exposure alters the insulin response, even among adults at high risk 
for developing T2D.91 Total IL-6 levels have predicted future development of T2D, but given the 
bi-functional nature of this molecule, it is unknown if this is a sign of direct inflammatory action 
or an attempt to modulate the effects of other inflammatory cytokines.92 
IL-6 levels rise linearly throughout pregnancy, and are thought to assist in the initiation 
of labor.93 In obese pregnancies, higher levels of IL-6 are seen in the serum and the placenta,94 
and often coincide with comorbidities including dyslipidemia, hypertension, and 
hyperinsulinemia without glucose dysregulation.95 In similar fashion, fetuses of obese mothers 
had higher cord blood levels of IL-6 at birth than fetuses born to lean mothers,96 though the 
veracity of an association with IL-6 and fetal birthweight has shown mixed results.8,97 
Mechanistically, high maternal levels of IL-6 may stimulate increased placental transfer of fatty 
acids and amino acids, which may contribute to fetal overnutrition.98 
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Purpose 
Though macrosomia is a well-established consequence of maternal hyperglycemia, there 
are several mediating factors, which may independently contribute to disproportionate fetal 
growth. Though nearly all major cytokines, along with maternal insulin resistance and obesity, 
have shown an association with fetal macrosomia, composite data in non-diabetic, overweight 
pregnant women is lacking. For mothers without overt GDM, but with the pattern of 
inflammation and insulin resistance seen in both obesity and pregnancy, it is worthwhile to study 
the relative contribution of each of these tenants. Such data may provide clinical insight into the 
pathology of macrosomia and potential therapeutic targets, while also creating a context in which 
to evaluate risk in this population. 
The purpose of this study is to determine if any association exists between the change in 
maternal insulin sensitivity (homeostatic model assessment of insulin resistance [HOMA-IR], 
fasting insulin, %B), and cytokine levels (TNF-α, IL-6, adiponectin) from mid to late pregnancy 
and infant adiposity at birth (WFL percentile, Ponderal Index) in non-diabetic, overweight and 
obese pregnant women.  Additionally, infant outcomes will be compared according to two sets of 
GDM diagnostic criteria, American Diabetes Association (ADA) and The American College of 
Obstetrics and Gynecology (ACOG). 
Hypotheses 
Null (H0) 
1. There is no relationship between the change in maternal insulin resistance (HOMA-IR) 
from 26-37 weeks of pregnancy and infant adiposity (WFL percentile and Ponderal 
Index). 
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2. There is no relationship between the change in maternal fasting insulin from 26-37 weeks 
of pregnancy and infant adiposity (WFL percentile and Ponderal Index). 
3. There is no relationship between the change in maternal β cell function (%B) from 26-37 
weeks of pregnancy and infant adiposity (WFL percentile and Ponderal Index). 
4. There is no relationship between the change in maternal TNF-α from 26-37 weeks of 
pregnancy and infant adiposity (WFL percentile and Ponderal Index). 
5. There is no relationship between the change in maternal IL-6 from 26-37 weeks of 
pregnancy and infant adiposity (WFL percentile and Ponderal Index). 
6. There is no relationship between the change in maternal adiponectin from 26-37 weeks of 
pregnancy and infant adiposity (WFL percentile and Ponderal Index). 
7. There is no relationship between the diagnosis of GDM according to ADA diagnostic 
criteria and infant anthropometry (weight, length, WFL percentile and Ponderal Index). 
8. There is no relationship between the diagnosis of impaired glucose tolerance (IGT) 
according to ACOG diagnostic criteria and infant anthropometry (weight, length, WFL 
percentile and Ponderal Index). 
Methods 
This analysis is a sub-study of a larger, NIH-funded intervention trial (5R21HL093532-
02) carried out in Cincinnati, Ohio (“DHA, Inflammation, and Insulin Sensitivity in Obese 
Pregnant Women”) and San Antonio, Texas (“Omega-3 Supplementation in High Risk 
Pregnancies to Improve the Health of Women and Their Babies”), under the direction of Dr. 
Debra Krummel and Dr. Teresa Powell, respectively.  The Institutional Review Boards of the 
University of Cincinnati (UC), Cincinnati Children’s Hospital Medical Center (CCHMC), and 
University of Texas Health Science Center at San Antonio (UTHSC) approved the study.   
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Subjects 
 For the intervention trials, English-speaking, pregnant women between the ages of 18-40 
years, who were 20-26 weeks gestation in a singleton pregnancy and had a pre-pregnancy BMI 
of ≥25, were recruited. Excluded were those with overt GDM which required insulin or 
pharmacological treatment; hypertension, inflammatory, vascular, or metabolic diseases; current 
or recent use of tobacco, illicit drugs, or inflammation-mediating drugs; and those who had 
experienced significant weight loss (>20 lbs.) prior to pregnancy. Subjects also had to be able to 
travel to the Clinical Translational Research Center (CTRC) at CCHMC or the FIRST Outpatient 
Research Unit (FORU) in San Antonio to participate in study activities. 
This substudy consisted of an analysis of data from women in the placebo arm of the 
larger study. Thus, 43 maternal/infant dyads with complete maternal metabolic and infant 
anthropometry data were included. None of the women in the final sample exhibited GDM 
according to the ACOG criteria. A total of 6 women in the final sample exhibited GDM 
according to the more stringent ADA criteria.   
Study Visit 
 In the larger study, three study visits were conducted, one at 26 weeks gestation, a second 
at 29-32 weeks gestation, and a third at 35-37 weeks gestation. This analysis uses biochemical 
data from the first and third study visits. Cincinnati participants completed their study visits at 
the GCRC at CCHMC, while San Antonio participants completed their study visits at the FORU 
clinic. Informed consent and HIPAA forms were completed at the initial study visit, prior to 
official study enrollment.   
 Biochemical data collected at both study visits included serum insulin, glucose, 
adiponectin, IL-6, and TNF-α. At the last study visit, an oral glucose tolerance test, using a 500-
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calorie, 75g carbohydrate meal, was also completed at this visit. Venous blood samples were 
drawn at 30, 60, 90, and 120 minutes after meal ingestion to determine insulin and glucose 
concentrations. Insulin was analyzed using radioimmunoassay; adiponectin, IL-6, and TNF-α, 
were analyzed using enzyme-linked immunoabsorbent assays. 
Insulin Resistance 
Derived from the OGTT are several calculated indices of insulin sensitivity that have 
been validated against the aforementioned clamp technique. One of these measures is HOMA-
IR, an index of insulin resistance calculated from fasting glucose and insulin values. First 
published by Matthews et al. in 1985, HOMA-IR was initially calculated using computer 
modeling or via a surrogate equation using the formula:  
[fasting glucose mmol/L X fasting insulin pmol/L / 22.5]99  
Today, the online 2004 Oxford HOMA-IR calculator is considered the most accurate way 
to extrapolate HOMA-IR (Levy), and provides three values based on fasting parameters: %B, 
which is a measure of β cell function, %S, which is a measure of peripheral and hepatic insulin 
sensitivity, and IR, which is the inverse of %S and reflects insulin resistance.100 HOMA-IR has 
been validated against the clamp technique in the second and third trimesters of pregnancy in 
obese and normal weight women.51,101 The online 2004 Oxford calculator was used to calculate 
%B and HOMA-IR for each participant.  
Infant Anthropometry  
  Infant birth data was obtained via self-report for the Cincinnati cohort and chart review 
for the San Antonio cohort. Infant weight for length percentile was determined using WHO 
Anthro Software, version 3.2.2. This software calculates percentiles based on gender and 
gestational age-specific WHO growth charts, which are suggested for use from birth until age 
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two by the Centers for Disease Control. (Website: http://www.cdc.gov/ 
growthcharts/who_charts.htm) We used the recommended cut-point of the 85th percentile for 
weight-for-length when determining infant overweight status. (CDC Training Manual: 
http://www.cdc.gov/nccdphp/dnpa/growthcharts/training /modules/module2/text/ 
module2print.pdf). Ponderal Index was used as an index of infant adiposity, having been 
validated in male and female infants of various ethnicities.102 Being scaled for height, it presents 
an advantage over BMI when assessing adiposity in infants.21 Ponderal Index was calculated 
using the formula: 
{100 x wtg / heightcm
3} 
A value at or above the 90th percentile103 was considered overweight according to this index.  
Statistical Analysis 
 All data is expressed as mean ± standard deviation, with the significance level set at 
<0.05. Dependent variables were infant WFL percentile and Ponderal Index percentile.  
Independent variables were change in maternal variables (HOMA-IR, insulin, %B, TNF-a, IL-6, 
and adiponectin). The absolute change in maternal variables was calculated as the concentration 
of the maternal variable obtained at SV3, minus the concentration of the same variable obtained 
at SV1. These variables were checked for normality (Kolmogorov-Smirnov P >0.05) and were 
transformed if this assumption was violated. Change in maternal insulin, adiponectin, and %B 
were found to be normal and were not transformed.  We used the minimum amount of 
transformation necessary to achieve normality. According to this approach, change in HOMA-IR 
and TNF-α were logarithmically transformed; change in IL-6 was transformed by square root. 
Normality was again tested and confirmed using the Kolmogorov-Smirnov test.  
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 To assess for potential confounding, Pearson’s correlations were run for infant outcome 
variables (WFL percentile, Ponderal Index) and maternal anthropometry (total gestational weight 
gain, pregravid BMI, pregravid weight).  Because pregravid BMI was significantly associated 
with WFL percentile (r=+.477, P=.001) and Ponderal Index (r=+.413, P=.006), it was used as a 
covariate in the correlation analysis. Infant outcome variables did not differ significantly by 
racial group or ethnicity according to an independent t-test; therefore, this was not controlled for 
subsequent analyses. Given that our variables demonstrated normality, we utilized the parametric 
statistic, Pearson’s correlation coefficient, to characterize the relationship between maternal 
change variables (insulin change, adiponectin change, %B change, HOMA-IR change, TNF-a 
change, IL-6 change) and infant anthropometric variables (WFL percentile and Ponderal Index).  
To determine whether maternal variables were associated with infant adiposity, t-tests 
were utilized to determine differences in mean maternal insulin change, adiponectin change, %B 
change, HOMA-IR change, TNF-a change, and IL-6 change by groupings of infant Ponderal 
Index (>/= 90th percentile). The same analysis was also run using weight for length percentile at 
birth (>/= 85th percentile) as the grouping variable.  Differences in infant outcomes were also 
examined according to both ADA and ACOG criteria. A t-test was used to determine mean 
differences in infant WFL percentile and Ponderal Index by groupings of normal glucose 
tolerance and impaired glucose tolerance, according to ACOG criteria (IGT defined as one value, 
fasting, one hour, or two hour exceeding the following cutpoints: 95 mg/dL, 180mg.dL, 155 
mg/dL). No subjects in the final sample had GDM according to ACOG criteria, which requires 
two abnormal values using the aforementioned cutpoints. An independent t-test was also used to 
determine mean differences in infant WFL percentile and Ponderal Index by groupings of normal 
glucose tolerance and GDM, according to ADA criteria (GDM defined as one value, fasting, one 
  23 
hour, or two hour exceeding the following cutpoints: 92mg/dL, 180mg/dL, and 152mg/dL). Six 
subjects in the final sample had GDM according to ADA criteria. Since the ADA criteria does 
not include a cutpoint for IGT, only the GDM/non-GDM designation was evaluated.  
 Data was analyzed using the software Statistical Package for the Social Sciences (version 
22, SPSS, Inc, Chicago, IL).  
Results 
 Maternal demographic and anthropometric data is summarized in Table 1. This data 
confirms that participants were either overweight or obese, defined as BMI >25kg/m2 and 
>30kg/m2, respectively.  The  distribution data for racial/ethnicity groups shows that half the 
sample is Chicano/Hispanic/Latino, with the remaining half nearly equally divided between non-
Hispanic black and non-Hispanic white. Slightly less than half of study participants were 
educated beyond the high school level.  
 Infant anthropometric data is summarized in Table 2. Birthweight was approximately 
average, among a wide range. Most infants were below the 85th and 90th threshold for WFL 
percentile and Ponderal Index, respectively. 
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Table 1. Sample Maternal Characteristics, (n=43) 
Variable N Mean ± SD Range 
Age (years) 43 27.9 ± 5.0 18-37 
Pregravid BMI (kg/m2) 43 35.9 ±7.0 25.8-57.7 
Level of education  Category % 
22 High School or 
Less 
58 
16 More Than High 
School 
42 
Race 12 Black, not 
Hispanic 
28 
9 White, not 
Hispanic  
21 
22 Chicano, Latino, 
Hispanic 
51 
 
Table 2. Infant Anthropometry at Birth (n=43) 
Variable N Mean ± SD Range 
Birthweight (g) 43 3447.3 ± 453.6 1955.0 - 4281.9 
Length (cm) 43 50.6 ± 2.6 43.1 - 55.0 
Weight for length (percentile)   Category % 
5 At or above 85th 12 
38 Below 85th 88 
Ponderal Index percentile 10 At or above 90th 23 
33 Below 90th  77 
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Maternal Glucose Metabolism and Infant Anthropometry 
Table 3. Maternal Glucose Metabolism in Second to Third Trimester  
Variable Late Second Trimester Late Third Trimester Mean Δ 
Mean ± SD Range  Mean ± SD Range 
Fasting glucose 
(mg/dL) 
82.3 ± 8.1 69-100 81.7 ± 9.3 69-109 -0.55  
Fasting insulin 
(uIU/mL) 
16.8 ± 8.6 5.2-43.2 21.7 ± 8.7 6.7-42.5 4.9  
% B 187.1 ± 57.1 88-351 229.5 ± 58.7 120-368 42.4 
HOMA-IR 2.1 ± 1.1 0.6-5.2 2.7 ± 1.1 0.8-5.3 0.58  
 
Table 4. Change in Maternal Glucose Metabolism and Infant Anthropometry at Birth 
Maternal 
Variables 
 
Infant Categories 
PI <90th 
%ile 
PI >/= 90th 
%ile 
P 
value 
WFL <85th 
%ile 
WFL >/=85th 
%ile 
P 
value 
Insulin Δ (uU) 
 
5.0 ± 5.1* 4.1 ± 9.3 0.69 4.8 ± 4.9 4.9 ± 13.4 0.98 
HOMA-IR Δ 
 
0.6 ± 0.6 0.5  ± 1.1 0.36 0.6 ± 0.6 0.5 ± 0.7 0.44 
%B Δ 43.7 ± 64.3 38.1 ± 64.9 0.81 42.1 ± 62.0 44.6 ± 84.0 0.93 
Mean +/- SD* 
 
HOMA-IR Change  
Maternal HOMA-IR change was not significantly correlated with infant WFL percentile 
(r=.084, P>0.05) or Ponderal Index (r=.046, P>0.05) when controlled for pregravid BMI. There 
was no difference in mean maternal HOMA-IR change between categories of infant WFL at 
birth (F (1, 41) = .612, P > 0.05) or Ponderal Index at birth (F (1, 41) = .853, P > 0.05). Thus, 
we cannot reject the null hypothesis, that there is no relationship between the change in maternal 
insulin resistance (HOMA-IR) from 26-37 weeks of pregnancy and infant adiposity (WFL 
percentile and Ponderal Index). 
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%B 
Maternal %B change was not significantly correlated with infant WFL percentile (r=-
0.136, P>0.05) or Ponderal Index (r=-0.192, P>0.05) when controlled for pregravid BMI. There 
was no difference in mean maternal %B change between categories of infant WFL at birth (F (1, 
41) = .007, P > 0.05) or Ponderal Index at birth (F (1, 41) = .057, P > 0.05). Thus we cannot 
reject the null hypothesis, that there is no relationship between the change in maternal β-cell 
function (%B) from 26-37 weeks of pregnancy and infant adiposity (WFL percentile and 
Ponderal Index). 
 
Maternal Cytokines and Infant Anthropometry 
Table 5. Maternal Cytokines in Second and Third Trimester 
Maternal 
Variable 
Late Second Trimester Late Third Trimester Mean Δ 
Mean ± SD Range  Mean ± SD Range 
Adiponectin 
(ug/mL) 
6.3 ± 3.1 1.8-21.1 5.4 ± 2.9 1.0-17.1 -0.9 
TNF-a (pg/mL)  3.9 ± 2.3 0.7-8.2 4.3 ± 3.1 0.5-14.1 0.4 
IL-6 (pg/mL) 4.8 ± 7.3 0.2-38.6 6.3 ± 8.8 0.4-47.5 1.4 
 
Table 6. Change in Maternal Cytokines and Infant Anthropometry at Birth 
Maternal 
Variable 
 
Infant Categories 
PI <90th 
%ile 
PI >/= 90th 
%ile 
P 
value 
WFL <85th 
%ile 
WFL >/=85th 
%ile 
P 
value 
Adiponectin Δ -0.89 ± 2.12*  -0.99 ± 1.64 0.90 -0.98 ± 2.04 -0.44 ± 1.78 0.58 
TNF-a Δ  0.52 ± 1.86 0.00 ± 1.25 0.50 0.41 ± 1.76 0.29 ± 1.70 0.60 
IL-6 Δ 1.30 ± 2.79 1.74 ± 4.66 0.57 1.64 ± 2.96 -0.36 ± 5.12 0.31 
Mean +/- SD* 
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Adiponectin 
Maternal adiponectin change was not significantly correlated with infant WFL percentile 
(r=0.206, P>0.05) or Ponderal Index (r=0.089, P>0.05) when controlled for pregravid BMI. 
There was no difference in mean adiponectin change between categories of infant WFL at birth 
(P > 0.05) or Ponderal Index at birth (P > 0.05). Thus we cannot reject the null hypothesis, that 
there is no relationship between the change in mean maternal adiponectin from 26-37 weeks of 
pregnancy and infant adiposity (WFL percentile and Ponderal Index). 
TNF-α 
Maternal TNF-α change was not significantly correlated with infant WFL percentile 
(r=0.028, P>0.05) or Ponderal Index (r=0.027, P>0.05) when controlled for pregravid BMI. 
There was no difference in mean maternal TNF-α change between categories of infant WFL at 
birth (P > 0.05) or Ponderal Index at birth (P > 0.05). Thus we cannot reject the null hypothesis, 
that there is no relationship between the change in TNF-α from 26-37 weeks of pregnancy and 
infant adiposity (WFL percentile and Ponderal Index). 
IL-6 
Maternal IL-6 change was not significantly correlated with infant WFL percentile (r=-
0.046, P>0.05) or Ponderal Index (r=-0.195, P>0.05) when controlled for pregravid BMI. There 
was no difference in mean maternal IL-6 change between categories of infant WFL at birth (P > 
0.05) or Ponderal Index at birth (P > 0.05). Thus we cannot reject the null hypothesis, that there 
is no relationship between the change in IL-6 from 26-37 weeks of pregnancy and infant 
adiposity (WFL percentile and Ponderal Index). 
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Clinical Diagnostic Thresholds and Infant Anthropometry  
ADA Diagnostic Guidelines  
Figure 1.  Prevalence of Gestational Diabetes per American Diabetes Association Criteria 
 
*GDM=gestational diabetes mellitus; NGT= normal glucose tolerance 
Table 5. Infant Outcomes by American Diabetes Association Diagnostic Guidelines 
Variable ADA Normal  
Mean ± SD 
ADA GDM  
Mean ± SD 
P value 
Birthweight (lb) 7.71 ± 1.1 7.26 ± 0.6 0.279 
Length (cm) 50.73 ± 2.7 50.26 ± 1.3 0.646 
Weight for length 
percentile 
43.1 ± 30.7 37.8 ± 24.8 0.650 
Ponderal Index 2.68 ± 0.39 2.59 ± 0.17 0.526 
 
There was no significant difference in mean birthweight (P > 0.05), length (P > 0.05), 
WFL percentile (P > 0.05), or Ponderal Index (P > 0.05) between categories of ADA diabetes 
diagnosis. This confirms the null hypothesis, that there is no relationship between the diagnosis 
of GDM according to ADA diagnostic criteria and infant anthropometry (weight, length, WFL 
percentile and Ponderal Index). 
 
NGT
N=35
81%
*GDM
N=8 
19%
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ACOG GDM Screening Guidelines 
Figure 2.  Prevalence of Impaired Glucose Tolerance per American College of Obstetrics 
and Gynecology Criteria 
 
*IGT=impaired glucose tolerance; NGT= normal glucose tolerance; GDM= gestational diabetes mellitus 
Table 6. Infant Outcomes by American College of Obstetrics and Gynecology Diagnostic 
Guidelines 
 
Variable N ACOG Normal 
Mean ± SD 
ADA IGT 
Mean ± SD 
P value 
Birthweight (lb) 43 7.65 ± 1.1 7.43 ± 0.6 0.639 
Length (cm) 43 50.68 ± 2.7 50.38 ± 1.1 0.797 
Weight for length percentile 43 42.1 ± 30.4 42.7 ± 25.1 0.962 
Ponderal Index 43 2.67 ± 0.38 2.64 ± 0.17 0.819 
 
There was no significant difference in mean birthweight (P > 0.05), length (P > 0.05), 
WFL percentile (P > 0.05), or Ponderal Index (P > 0.05) between categories of AGOC 
diagnosis. This confirms the null hypothesis, that there is no relationship between the diagnosis 
of IGT according to ACOG diagnostic criteria and infant anthropometry (weight, length, WFL 
percentile and Ponderal Index). 
 
 
NGT
N=37
86%
*IGT
N=6
14%
GDM
N=0
0%
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Discussion 
 The maternal adiponectin levels observed in this sample at 26 weeks (6.3ug/mL) and 35-
37 weeks (5.4ug/mL) were lower than those observed in normal weight pregnancy at the same 
timepoints (11.3ug/mL and 9.7ug/mL, respectively) with a smaller trajectory of change from mid 
to late pregnancy.104 Our observed adiponectin levels at 35-37 weeks were more closely aligned 
with third trimester values among class II obese pregnant women without GDM or pre-eclampsia 
(7.2 ug/mL).105 The maternal IL-6 levels observed in this sample in late pregnancy (6.3pg/mL) 
were significantly lower than those observed in pregnancies complicated by diabetes 
(13.7pg/mL).106 TNF-a among our participants was similar in late pregnancy to levels of GDM 
and non-GDM pregnancies, as studies have shown these values often do not differ between 
GDM gravidas and healthy controls.107-109 The cytokine picture of our participants bears likeness 
to a normoglucotolerant, albeit obese, pregnant population.  
 The change in maternal fasting insulin seen in our sample (+4.9 units) is more closely 
aligned with a GDM population, and even exceeds the increase seen in a sample of diabetic 
gravidas (+2.0 units).110 The fasting insulin levels for the second and third trimester observed in 
our study (16.8 uIu/mL and 21.7 uIu/mL) are also higher than both NGT overweight pregnancies 
(11.8 uIu/mL and 10.9 uIu/mL) and pregnancies complicated by GDM (12.2 uIu/mL and 14.2 
uIu/mL).111 Insulin resistance measured by HOMA-IR increased from the second to third 
trimesters in our sample (+0.6 units), as did β cell activity (+ 42.4 percentage units). This is 
comparable to the absolute increase of insulin resistance seen in a multi-ethnic population of 
overweight pregnant women with GDM, who saw an increase of 0.6 HOMA-IR units from 20-28 
weeks of pregnancy.110 The increase in β-cell function in our study population was slightly 
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higher than that in seen in this same GDM sample, where the median %B increase was +30 
units.110 
 While our sample demonstrates normal to slightly elevated levels of cytokines, the 
picture of insulin resistance is bleaker, with fasting insulin and the trajectory of insulin resistance 
more severe than values seen among average GDM pregnancies. Yet, according to the more 
traditional ACOG criteria, none of these subjects presented with the hyperglycemia indicative of 
GDM. It is plausible that these subjects are teetering on the edge of GDM development, 
protected only by the continued preservation of β-cell utility. This milieu is evidenced by sharply 
increasing β-cell function and elevated fasting insulin, which may be protecting the serum 
glycemic state, at least for a time. Should the β cell toxicity characteristic of overworked islet 
cells emerge, this population may be unable to continue to compensate for the increasing 
resistance to insulin in the peripheral tissues. This hypothesis is consistent with Catalano’s model 
of GDM development, where a blunted insulin response in combination with peripheral insulin 
resistance is necessary for apparent hyperglycemia.13 
 Rather than traditional weight-based measures of infant macrosomia, we examined 
weight to length proportions, using both a simple, sex-specific ratio (WFL percentile) and a 
calculated, height-corrected index (Ponderal Index). As primarily research measures, readily 
available reference data for these specific indices of adiposity are lacking. Nonetheless, Ponderal 
Index is still superior to BMI for infant adiposity assessment and weight-based measures of 
macrosomia, as it scales for short stature and has been correlated with other determinants of fetal 
growth.112 In our sample, 12% (5 of 43) of infants were at or above the 85th percentile for weight 
for length, while 23% (10 of 43) were at or above the 90th percentile for Ponderal Index. The 
proportion of infants exceeding adiposity cutpoints in this study (12 or 23%) more closely 
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mirrors the national rates of macrosomia among obese mothers (13.3%) than national rates of 
macrosomia for normal weight mothers (8.3%).113 The small total number of high WFL/Ponderal 
Index infants is a limitation of this study, despite rates being in line with national averages.  
 The unique makeup of this sample allowed for the assessment of the differing GDM 
diagnostic criteria in overweight and obese pregnant women. Though no study participant was 
diagnosed with GDM according to ACOG criteria, which was utilized in our inclusion/exclusion 
criteria, 14% of the sample (6 participants) exhibited one abnormal value among the fasting, 1 
hour, and 2 hour time points during the OGTT, which the ACOG criteria defines as IGT. There 
were no significant differences in infant anthropometry between NGT and IGT according to 
ACOG criteria. When the newer and more highly conservative ADA criteria was used to stratify 
the sample, 19% of the sample (8 participants) exhibited one abnormal value, which is an 
automatic GDM designation per this criteria. No significant differences in infant outcome 
variables were observed between groupings of the ADA criteria. These findings bring into 
question the relevancy of the NGT/IGT designation of the ACOG criteria and the GDM/non-
GDM designation of the ADA criteria in offspring of obese, pregnant women. These findings 
align with the results a recent analysis of 599 terms infants, where GDM status was not an 
independent predictor of adiposity measured by air displacement plethysmography.114 Adding to 
the existing criticism of the ADA guidelines on theoretical grounds115 are incidences of 
macrosomia where up to 49% of mothers have tested normal during a 50g glucose challenge 
test.116 Despite numerous studies belaboring the point, the optimal diagnostic threshold for GDM 
diagnosis remains unclear,117 hearkening to clinical individuality and the potential of other 
maternal factors to play a role in infant growth and adverse pregnancy outcomes.   
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Infant adiposity was not related to significant changes in maternal glucose tolerance 
(fasting insulin, HOMA-IR, %B) Taken together, these findings are in agreement with new 
evidence questioning the contribution of maternal glucose tolerance to infant size at birth, and 
challenging the pervasive perception of a direct linear relationship between maternal glucose and 
infant size. A recent study found that maternal fasting glucose was related to adiposity in female 
infants, but had little to no effect on male infant adiposity.118 Maternal lipid metabolism is also 
being illuminated as a macrosomic risk factor, potentially even more significant than maternal 
hyperglycemia.119 To date, more than 25 single nucleotide polymorphisms have been identified 
as being associated with infant adiposity at birth, all while controlling for the impact of maternal 
glycemia, illuminating the role of genetic predisposition in fetal growth.120 Additionally, a trial 
with Hispanic gravidas found that in obese mothers without hyperglycemia, increased placental 
size, not maternal glucose tolerance, may be responsible for increased fetal nutrient transfer and 
umbilical expression of GLUT-1 transporters.121 Very recent critical reappraisals of the 
relationship between GDM and future obesity and disease risk of the offspring have questioned 
even this connection, and criticized older studies for failing to control for critical confounders 
such as maternal and paternal BMI.122 Genetics, placental function, and maternal lipid 
metabolism are important factors which may outshine maternal glucose in determining infant 
size at birth.  
 In the present sample, no statistical relationship between maternal cytokines and infant 
outcomes was observed. In similar samples of obese women, both with and without GDM, 
adiponectin was not consistently associated with infant size at birth.7,123 IL-6 and TNF-α are 
more consistently associated with infant adiposity,97,124 and the lack of an association seen in this 
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study may be a result of low power (n=43), or the potential paradoxical role of these cytokines in 
fetal growth restriction.125 
Conclusion 
 Despite being classified as obese prior to pregnancy, the mothers included in this analysis 
did not exhibit the hyperglycemia diagnostic of GDM. However, the elevated insulin and β-cell 
function may describe a unique population where intervention to increase insulin sensitivity and 
decrease the β-cell workload may stave off pending β- cell failure. Even among women with 
impaired fasting glucose, no differences in infant adiposity were observed, nor did infant 
adiposity differ according to levels of maternal cytokines. These findings lend credence to 
emerging theories relating to additional genetic, placental, and metabolic factors which may 
determine infant size, while challenging the assumption that obese pregnant women are 
unequivocally at risk for macrosomic births.    
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